Daiichi Sankyo weekly recap highlights DESTINY—Lung04 and Enhertu

DESTINY—Lung04 data: first-line HER2-mutant NSCLC PFS 14.3 vs 8.3 months (HR 0.63) and 70% ORR in AstraZeneca-combined results. Enhertu: CHMP adjuvant nod and routine NHS reimbursement in England for advanced HER2-positive/low breast cancer.